查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012772

抗肥胖處方藥市場：依藥物類別、給藥途徑、最終用戶和通路分類－2026-2032年全球市場預測

Anti-obesity Prescription Drugs Market by Drug Class, Administration Route, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，抗肥胖處方藥市場價值將達到 72.5 億美元，到 2026 年將成長至 78.4 億美元，到 2032 年將達到 127.7 億美元，複合年成長率為 8.40%。

主要市場統計數據
基準年 2025 72.5億美元
預計年份：2026年 78.4億美元
預測年份 2032 127.7億美元
複合年成長率 (%) 8.40%

簡要概述正在改變處方箋抗減肥藥和相關人員決策的臨床、商業性和營運趨勢。

在科學突破、新的給藥方法以及支付方和政策制定者日益嚴格的審查的推動下，處方箋抗肥胖藥物的治療和商業性格局正經歷著顯著的變革時期。臨床醫生擴大將新的荷爾蒙療法與對特定患者群體仍然有效的現有藥物一起納入治療方案。同時，醫療設備的創新和新型口服製劑正在改變治療方法和監測方式，為提高用藥依從性和病人參與創造了新的干涉點。

科學突破、管理方法創新和綜合數位支援系統如何重新定義抗肥胖藥物治療的治療策略和護理路徑。

近年來，科學的進步已將藥物治療肥胖症的模式從症狀治療轉變為基於機制和生理學的治療方法，這些方法能夠影響食慾調節、飽足訊號傳導和能量平衡。腸促胰島素療法的出現及其臨床療效加速了人們對多方面治療方法和聯合策略的興趣，促使研發人員探索現有的胜肽類藥物以及針對互補路徑的新一代分子。因此，臨床試驗設計、終點選擇和長期安全性監測均已發展演變，以反映人們對持續體重管理和心血管代謝效益的期望。

對近期美國關稅措施對全球供應鏈、製造決策以及取得處方箋抗減肥藥。

主要經濟體的政策調整和關稅措施可能會顯著重塑複雜治療藥物的全球供應鏈和成本結構，尤其是在活性成分、生物製藥原料和成品在生產過程中需要跨越多個國界的情況下。 2025年美國的關稅環境為處方箋抗肥胖藥物的籌資策略、契約製造關係和庫存計畫帶來了新的考量。各公司正在重新評估供應商集中度帶來的風險，並探索替代製造地，以減輕貿易政策變化的影響。

透過進行基於細分的詳細分析，將藥物類別、劑型、分銷管道和最終用戶環境聯繫起來，我們可以製定準確的開發和商業化策略。

了解患者群體和產品劑型對於最佳化整個抗肥胖藥物組合的臨床開發、商業化和分銷策略至關重要。藥物類別包括Amylin類似物（如Pramlintide） 、一系列GLP-1促效劑（如Dulaglutide、Exenatide、Liraglutide和Semaglutide） 、以奧利司他為代表的脂肪酶抑制劑以及5-羥色胺受體調變器（如氯卡色林）。每個類別都具有獨特的療效、安全性和耐受性特徵，這些特徵指南藥物的市場定位和處方醫生的選擇。此外，藥物的使用模式也因製劑形式和給藥途徑而異。對於尋求長效或劑量可調治療方法的患者和醫護人員而言，自動注射器、預填充注射筆和傳統的管瓶/注射器劑型更受歡迎。另一方面，口服膠囊和片劑為不願注射的患者提供了更大的便利，並為基層醫療的應用提供了機會。

區域比較觀點，突顯美洲、歐洲、中東、非洲和亞太地區在監管預期、支付方趨勢和分銷方面的細微差異。

區域趨勢正以獨特的方式塑造著監管路徑、支付方參與以及更廣泛的臨床實踐生態系統。在美洲，監管機構和支付者正在仔細評估長期安全性和成本效益，而醫療服務提供者網路正在迅速採用整合藥物治療和行為介入的多模態護理模式。該地區的商業基礎設施既支援專科診所服務，也支持透過遠端醫療擴大分銷範圍，從而促進了利用數位化用藥依從性工具的靈活上市策略。

本報告透過公司概況和合作結構，揭示了整合開發、設備工程和數位夥伴關係如何創造競爭差異化和業務永續營運。

競爭格局涵蓋傳統製藥企業、生物製劑專家、新興生物技術創新者、醫療設備製造商、契約製造組織 (CMO) 和數位醫療供應商。在生物製劑開發、注射器器械工程和低溫運輸物流方面擁有綜合能力的公司，在將肽類療法推向市場時具有明顯的商業優勢。同時，靈活的生物技術公司正在開發新的作用機制和新製劑，並經常利用策略夥伴關係和許可授權來獲得生產規模和商業基礎設施。

為製藥、製造和商業團隊制定以行動為導向的策略重點，以協調證據產生、供應彈性和支付方夥伴關係，實現永續的藥物取得。

產業領導企業應優先考慮整合臨床定位、生產韌性和支付方參與的整合策略，以保持競爭優勢。首先，投資創建除對照臨床試驗之外的可靠安全性和真實世界數據 (RWE) 至關重要，這有助於支持保險覆蓋範圍談判並證明患者的長期益處。在累積證據的同時，擴大醫療設備和製劑選擇範圍，可以透過滿足不同的給藥偏好和依從性需求來擴大目標患者群體。

對嚴謹、多方面的調查方法進行了透明的解釋，該方法結合了臨床文獻回顧、專家訪談、生產評估和資料檢驗。

本研究採用多面向方法，結契約儕審查的臨床文獻、監管申報文件、指導文件和公共聲明的系統性回顧，以及有針對性的初步研究。研究人員與內分泌科醫生、基層醫療醫生、監管專家、供應鏈高管、支付方和患者權益組織代表進行了專家諮詢，以檢驗關鍵趨勢和實際影響。在生產和物流評估方面，研究人員與契約製造製造商、醫療設備供應商和低溫運輸營運商進行了技術簡報，以評估產能考量和風險緩解策略。

全面概述臨床創新、供應韌性和支付方參與如何相互交織，從而決定抗減肥藥的長期可及性和策略性成功。

處方箋抗減肥藥的未來取決於科學創新、新的給藥模式以及不斷變化的政策和支付方期望，所有這些因素共同創造了機遇，同時也帶來了挑戰。利用生理機制的新治療方法正在促使人們重新思考長期管理策略，而給藥方法和數位化支持的進步則拓寬了醫療服務和藥物依從性支持工具的範圍。同時，監管和採購趨勢要求企業提供更強力的真實世界數據（REW），並建立能夠抵禦地緣政治和貿易政策衝擊的彈性供應鏈。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：抗肥胖處方藥市場：依藥物類別分類

  • Amylin類似物
    • Pramlintide
  • GLP-1促效劑
    • Dulaglutide
    • Exenatide
    • Liraglutide
    • Semaglutide
  • 脂肪酶抑制劑
    • 奧利司他
  • 血清素受體調變器
    • 氯卡色林

第9章：抗肥胖處方藥市場：依給藥途徑分類

  • 注射藥物
    • 自動注射器
    • 預填充筆
    • 管瓶和注射器
  • 口服藥物
    • 膠囊
    • 藥片

第10章：抗肥胖處方藥市場：依最終用戶分類

  • 門診部
  • 居家照護設施
  • 醫院
  • 專科診所
    • 內分泌診所
    • 全科診所
    • 減重診所

第11章：抗肥胖處方藥市場：依通路分類

  • 離線
  • 線上

第12章：抗肥胖處方藥市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：抗肥胖處方藥市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 抗肥胖處方藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國：抗肥胖處方藥市場

第16章 中國：抗肥胖處方藥市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alizyme Limited
  • Amgen Inc.
  • AstraZeneca PLC
  • BioCon Limited
  • Boehringer Ingelheim International GmbH
  • CHEPLAPHARM Arzneimittel GmbH
  • Currax Pharmaceuticals LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gelesis Holdings, Inc.
  • GlaxoSmithKline PLC
  • Hanmi Pharm.Co., Ltd.
  • HK inno.N Corporation
  • Innovent Biologics, Inc.
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Orexigen Therapeutics, Inc.
  • Pfizer Inc.
  • Reddy's Laboratories Limited
  • Rhythm Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals Company Limited
  • Verdiva Pharma Inc.
  • Vivus LLC
  • Zydus Lifesciences Limited
Product Code: MRR-4358BACA7FD1

The Anti-obesity Prescription Drugs Market was valued at USD 7.25 billion in 2025 and is projected to grow to USD 7.84 billion in 2026, with a CAGR of 8.40%, reaching USD 12.77 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.25 billion
Estimated Year [2026] USD 7.84 billion
Forecast Year [2032] USD 12.77 billion
CAGR (%) 8.40%

A concise orientation to the evolving clinical, commercial, and operational dynamics transforming prescription anti-obesity therapeutics and stakeholder decision-making

The therapeutic and commercial landscape for prescription anti-obesity drugs has entered a period of pronounced transformation driven by scientific breakthroughs, novel delivery formats, and intensified payer and policy scrutiny. Clinicians are increasingly integrating newer hormone-based agents into care pathways alongside legacy medications that continue to serve specific patient segments. Meanwhile, device innovations and novel oral formulations are changing how therapies are administered and monitored, creating fresh touchpoints for adherence interventions and patient engagement efforts.

Against this backdrop, stakeholders from biotech innovators to hospital systems must re-evaluate operational assumptions. Supply chains that were once linear are now subject to new sourcing requirements and capacity pressures, and the competitive environment is characterized by rapid product differentiation and strategic collaborations. The evolving interplay of clinical efficacy, tolerability profiles, and convenience is reshaping prescribing behavior and care delivery models, requiring cross-functional alignment between clinical development, regulatory affairs, commercial teams, and distribution partners.

How scientific breakthroughs, delivery innovations, and integrated digital support systems are collectively redefining therapeutic strategies and care pathways in anti-obesity pharmacotherapy

Recent scientific advances have shifted the paradigm of pharmacologic obesity management from symptomatic interventions to mechanistic, physiology-based approaches that impact appetite regulation, satiety signaling, and energy homeostasis. The emergence and clinical validation of incretin-based therapies have accelerated interest in multimodal regimens and combination strategies, prompting developers to explore both established peptide classes and next-generation molecules targeting complementary pathways. As a result, clinical trial design, endpoint selection, and long-term safety monitoring have all evolved to reflect expectations for sustained weight management and cardiometabolic benefit.

Concurrently, the realm of drug delivery and patient experience has seen meaningful innovation. Long-acting injectables, patient-friendly autoinjectors and prefilled pens, and improved oral formulations have reframed adherence conversations and enabled new points of care. Digital tools for adherence monitoring, remote titration, and behavioral support are increasingly integrated with pharmacotherapy, reinforcing therapeutic value through improved outcomes. Finally, market access and reimbursement dialogues now center on real-world effectiveness, health-economic evidence, and patient stratification, which together influence formulary placement and clinical adoption trajectories.

Assessment of the cascading operational consequences of recent United States tariff measures on global supply chains, manufacturing decisions, and access pathways for prescription anti-obesity therapeutics

Policy adjustments and tariff actions in major economies can materially reconfigure global supply chains and cost structures for complex therapeutics, particularly when active pharmaceutical ingredients, biologics manufacturing inputs, and finished-dose forms cross multiple borders during production. The 2025 tariff environment in the United States has introduced new considerations for sourcing strategies, contract manufacturing relationships, and inventory planning for prescription anti-obesity products. Companies are reassessing supplier concentration risks and exploring alternative manufacturing footprints to mitigate exposure to trade-policy volatility.

This recalibration has implications for manufacturing lead times, quality assurance oversight, and total landed costs, which in turn affect procurement strategies and the commercial calculus for entry into specific channels. In response, many stakeholders are pursuing dual-sourcing arrangements, nearshoring of critical processes, and renegotiation of commercial terms with logistics providers. Importantly, regulatory compliance and supply-chain traceability have become central to these efforts, as firms balance cost containment with the necessity of maintaining uninterrupted patient access to therapies across distribution networks.

Deep segmentation-driven analysis linking drug classes, administration formats, distribution channels, and end-user environments to inform precise development and commercialization tactics

Understanding patient segments and product modalities is essential to tailoring clinical development, commercialization, and distribution strategies across the anti-obesity portfolio. Drug classes span amylin analogs such as pramlintide, a range of GLP-1 agonists including dulaglutide, exenatide, liraglutide, and semaglutide, lipase inhibitors exemplified by orlistat, and serotonin receptor modulators like lorcaserin; each class presents distinct efficacy, safety, and tolerability profiles that inform positioning and prescriber choice. Moreover, formulation and administration route drive differential adoption patterns: injectables delivered via autoinjectors, prefilled pens, and traditional vial-and-syringe formats attract patients and providers seeking longer-acting or titratable therapies, while oral capsules and tablets offer convenience for those averse to injections and opportunities for primary care adoption.

Distribution channels and end-user settings further stratify opportunity and risk. Traditional offline channels remain important for clinical oversight, patient education, and cold-chain handling, while online pharmacies and telehealth-enabled dispensing expand access and convenience, particularly for chronic management. End users range from ambulatory care centers and hospitals to home-care settings and specialty clinics; within specialty clinics, endocrinology practices, general practice clinics, and weight-loss clinics each demand tailored support, educational materials, and clinical protocols. Therefore, commercialization strategies must be nuanced, aligning product attributes with administration preferences, channel dynamics, and the specific needs of prescriber types and care settings.

Comparative regional perspectives highlighting regulatory expectations, payer dynamics, and distribution nuances across the Americas; Europe, Middle East & Africa; and Asia-Pacific territories

Regional dynamics shape regulatory pathways, payor interactions, and the broader ecosystem of clinical practice in distinctive ways. In the Americas, regulatory agencies and payers are closely evaluating long-term safety and cost effectiveness, while provider networks are rapidly adopting multimodal care models that integrate pharmacotherapy with behavioral interventions. The commercial infrastructure in this region supports both specialty clinic delivery and expanding telehealth-enabled distribution, encouraging flexible launch strategies that leverage digital adherence tools.

Europe, the Middle East & Africa present heterogeneous regulatory and reimbursement landscapes that require localized evidence generation and engagement approaches. Many countries emphasize rigorous health-economic assessments and comparative effectiveness data, which influences pricing negotiations and formulary access. In this region, partnerships with regional distributors and specialized clinics are often essential to navigate fragmented delivery channels. Asia-Pacific markets exhibit diverse maturity levels; some countries are advancing rapid uptake of cutting-edge therapies supported by integrated hospital systems and strong manufacturing capabilities, while others are prioritizing cost containment and domestic production. Supply-chain resilience, regulatory harmonization efforts, and culturally adapted patient-support programs are therefore critical considerations across these geographies.

Strategic company profiles and alliance architectures that reveal how integrated development, device engineering, and digital partnerships are shaping competitive differentiation and operational resilience

The competitive landscape encompasses legacy pharmaceutical manufacturers, biologics specialists, emerging biotech innovators, device makers, contract manufacturing organizations, and digital health vendors. Firms with integrated capabilities across biologics development, device engineering for injectables, and cold-chain logistics possess distinct operational advantages when bringing peptide-based therapies to market. Simultaneously, agile biotech companies are advancing novel mechanisms of action and new formulations, often leveraging strategic partnerships or licensing deals to access manufacturing scale and commercial infrastructure.

Supply-chain and contract manufacturing partners are increasingly visible as pivotal contributors to product availability and cost efficiency. Device manufacturers that can deliver patient-centered autoinjectors and user-friendly pens enhance adherence and support provider uptake. Digital therapeutics vendors offering behavioral coaching, remote titration, and adherence analytics are becoming important adjuncts to pharmacotherapy, enabling value demonstrations to payers and providers. Across the sector, collaborative models-ranging from co-development agreements to distribution partnerships-are central to de-risking launches and accelerating time to patient access.

Action-oriented strategic priorities for pharmaceutical, manufacturing, and commercial teams to align evidence generation, supply resilience, and payer partnerships for sustained access

Industry leaders should prioritize integrated strategies that align clinical positioning, manufacturing resilience, and payer engagement to sustain competitive advantage. First, investing in robust safety and real-world evidence generation that extends beyond controlled trials will be essential to support coverage conversations and demonstrate long-term patient benefit. Parallel to evidence generation, expanding device and formulation options can broaden the addressable patient base by meeting diverse administration preferences and adherence needs.

Operationally, diversifying supply-chain footprints via geographically distributed manufacturing, strategic contract manufacturing partnerships, and enhanced raw-material traceability will reduce exposure to policy shocks and capacity constraints. Commercial teams should deploy channel-specific approaches that integrate in-clinic initiation protocols with telehealth follow-up and digital adherence supports to optimize continuity of care. Finally, pursuing selective collaborations with payers and health systems to develop outcomes-based contracts or risk-sharing agreements can facilitate access while aligning incentives around measurable clinical outcomes and cost offsets.

Transparent description of the rigorous multi-method research approach combining clinical literature review, expert interviews, manufacturing assessments, and data triangulation

This research synthesizes a multi-method approach combining a structured review of peer-reviewed clinical literature, regulatory filings, guidance documents, and public policy statements with targeted primary research. Expert consultations were conducted with clinicians across endocrinology and primary care, regulatory specialists, supply-chain executives, payers, and patient advocacy representatives to validate key trends and operational implications. Manufacturing and logistics assessments drew on technical briefings with contract manufacturers, device suppliers, and cold-chain providers to assess capacity considerations and mitigation strategies.

Data triangulation and cross-validation techniques were used to reconcile qualitative insights with publicly available clinical and regulatory information. The study applied segmentation mapping to align drug-class attributes with delivery modalities, channel dynamics, and end-user needs. Quality assurance protocols included peer review by subject-matter experts, consistency checks across regional assessments, and verification of factual statements against authoritative regulatory documents. Ethical considerations and confidentiality safeguards were maintained for all primary interviews and proprietary inputs.

A synthesized closing perspective on how clinical innovation, supply resilience, and payer engagement converge to determine long-term access and strategic success in anti-obesity therapeutics

The trajectory of prescription anti-obesity therapeutics is defined by scientific innovation, new delivery models, and shifting policy and payer expectations that together create both opportunity and complexity. Emerging therapies that leverage physiologic mechanisms have catalyzed rethinking of long-term management strategies, while advances in administration and digital support expand the spectrum of care settings and adherence tools. At the same time, regulatory scrutiny and procurement dynamics are compelling firms to produce stronger real-world evidence and to design resilient supply chains that can withstand geopolitical and trade-policy disruptions.

Decision-makers must therefore adopt integrated playbooks that bring clinical evidence, manufacturing strategy, and commercial execution into alignment. By doing so, organizations can better match product attributes to patient needs, secure reliable access across channels and geographies, and demonstrate value to payers and providers. The coming years will reward stakeholders who combine clinical credibility with operational agility and partnership-driven commercialization, enabling sustainable patient access to effective anti-obesity pharmacotherapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-obesity Prescription Drugs Market, by Drug Class

  • 8.1. Amylin Analogs
    • 8.1.1. Pramlintide
  • 8.2. GLP-1 Agonists
    • 8.2.1. Dulaglutide
    • 8.2.2. Exenatide
    • 8.2.3. Liraglutide
    • 8.2.4. Semaglutide
  • 8.3. Lipase Inhibitors
    • 8.3.1. Orlistat
  • 8.4. Serotonin Receptor Modulators
    • 8.4.1. Lorcaserin

9. Anti-obesity Prescription Drugs Market, by Administration Route

  • 9.1. Injectables
    • 9.1.1. Auto-Injectors
    • 9.1.2. Prefilled Pens
    • 9.1.3. Vials And Syringes
  • 9.2. Orals
    • 9.2.1. Capsules
    • 9.2.2. Tablets

10. Anti-obesity Prescription Drugs Market, by End User

  • 10.1. Ambulatory Care Centers
  • 10.2. Home Care Settings
  • 10.3. Hospitals
  • 10.4. Specialty Clinics
    • 10.4.1. Endocrinology Clinics
    • 10.4.2. General Practice Clinics
    • 10.4.3. Weight Loss Clinics

11. Anti-obesity Prescription Drugs Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Anti-obesity Prescription Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anti-obesity Prescription Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anti-obesity Prescription Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Anti-obesity Prescription Drugs Market

16. China Anti-obesity Prescription Drugs Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alizyme Limited
  • 17.6. Amgen Inc.
  • 17.7. AstraZeneca PLC
  • 17.8. BioCon Limited
  • 17.9. Boehringer Ingelheim International GmbH
  • 17.10. CHEPLAPHARM Arzneimittel GmbH
  • 17.11. Currax Pharmaceuticals LLC
  • 17.12. Eli Lilly and Company
  • 17.13. F. Hoffmann-La Roche Ltd.
  • 17.14. Gelesis Holdings, Inc.
  • 17.15. GlaxoSmithKline PLC
  • 17.16. Hanmi Pharm.Co., Ltd.
  • 17.17. HK inno.N Corporation
  • 17.18. Innovent Biologics, Inc.
  • 17.19. Merck & Co., Inc.
  • 17.20. Novo Nordisk A/S
  • 17.21. Orexigen Therapeutics, Inc.
  • 17.22. Pfizer Inc.
  • 17.23. Reddy's Laboratories Limited
  • 17.24. Rhythm Pharmaceuticals, Inc.
  • 17.25. Takeda Pharmaceutical Company Limited
  • 17.26. Teva Pharmaceuticals Company Limited
  • 17.27. Verdiva Pharma Inc.
  • 17.28. Vivus LLC
  • 17.29. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 206. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 207. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 208. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 209. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 211. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 212. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 213. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 215. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 242. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 243. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 244. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 245. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 246. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 247. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 248. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 249. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 251. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 254. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 255. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 256. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 257. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 258. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 259. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 260. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 261. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 263. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)